[go: up one dir, main page]

WO2013045668A3 - Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c - Google Patents

Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c Download PDF

Info

Publication number
WO2013045668A3
WO2013045668A3 PCT/EP2012/069272 EP2012069272W WO2013045668A3 WO 2013045668 A3 WO2013045668 A3 WO 2013045668A3 EP 2012069272 W EP2012069272 W EP 2012069272W WO 2013045668 A3 WO2013045668 A3 WO 2013045668A3
Authority
WO
WIPO (PCT)
Prior art keywords
regimen
immunotherapy composition
virus infection
treating hepatitis
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/069272
Other languages
English (en)
Other versions
WO2013045668A2 (fr
Inventor
Géraldine HONNET
Bernard BURTIN
Delphine AGATHON
Jean-Marc Limacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of WO2013045668A2 publication Critical patent/WO2013045668A2/fr
Publication of WO2013045668A3 publication Critical patent/WO2013045668A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le domaine de l'immunothérapie et plus particulièrement une composition comprenant des antigènes HCV non-structuraux (NS) ou un(des) vecteur(s) d'expression de ceux-ci destinés à être utilisés pour traiter une infection par le virus de l'hépatite C (HCV). La présente invention concerne également un schéma thérapeutique comprenant l'étape d'administration à un sujet d'une telle composition immunothérapeutique ainsi qu'un kit de parties comprenant une pluralité de récipients et des instructions de mise en œuvre dudit schéma thérapeutique. La composition immunothérapeutique, le kit et le schéma thérapeutique peuvent être utilisés en association avec une thérapie antivirale (par exemple une thérapie avec un interféron et/ou de la ribavirine).
PCT/EP2012/069272 2011-09-29 2012-09-28 Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c Ceased WO2013045668A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP11306248 2011-09-29
EP11306248.3 2011-09-29
EP11306433.1 2011-11-04
EP11306433 2011-11-04
EP11306441.4 2011-11-07
EP11306441 2011-11-07

Publications (2)

Publication Number Publication Date
WO2013045668A2 WO2013045668A2 (fr) 2013-04-04
WO2013045668A3 true WO2013045668A3 (fr) 2013-06-06

Family

ID=46924495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/069272 Ceased WO2013045668A2 (fr) 2011-09-29 2012-09-28 Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c

Country Status (2)

Country Link
TW (1) TW201321016A (fr)
WO (1) WO2013045668A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136740A1 (en) * 2000-08-17 2002-09-26 Matti Sallberg Vaccines containing ribavirin and methods of use thereof
US20070269460A1 (en) * 2003-06-05 2007-11-22 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
WO2009056535A2 (fr) * 2007-10-29 2009-05-07 Genimmune N.V. Procédés et kits permettant d'induire une réponse de ltc en utilisant un schéma de primovaccination/rappel
WO2010117936A1 (fr) * 2009-04-06 2010-10-14 Schering Corporation Associations d'un inhibiteur du virus de l'hépatite c (vhc), tels des dérivés pyrroliques bicycliques, et d'un agent thérapeutique

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650838A1 (fr) 1989-08-09 1991-02-15 Transgene Sa Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
JP2001506126A (ja) 1996-12-13 2001-05-15 シェーリング コーポレイション ウイルスの精製方法
WO1998056415A1 (fr) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Saponines purifiees servant d'adjuvants oraux
JP3864610B2 (ja) 1998-05-21 2007-01-10 旭硝子株式会社 水分散型撥水撥油剤組成物およびその製造方法
WO2000040702A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
IL159454A0 (en) 2001-06-22 2004-06-01 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
US7247472B2 (en) 2001-11-21 2007-07-24 The Trustees Of The University Of Pennsylavania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
SI1711518T1 (sl) 2004-01-23 2010-04-30 Inst Di Richerche Di Biolog Mo Ĺ impanzji adenovirusni nosilci cepiva
WO2007077256A1 (fr) 2006-01-05 2007-07-12 Transgene S.A. Transcriptase inverse de la télomérase aviaire
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
CN101460627B (zh) 2006-06-20 2012-09-05 特朗斯吉有限公司 制备痘病毒的方法以及痘病毒组合物
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
EP2176398B1 (fr) 2007-07-03 2016-12-28 Transgene SA Lignées cellulaires aviaires immortalisées
SI2220241T1 (sl) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
HRP20170395T1 (hr) 2007-11-28 2017-05-05 The Trustees Of The University Of Pennsylvania Podporodice adenovirusa b majmuna sadv-28, 27,-29,-32,-33, i -35 i njihove primjene
KR101614369B1 (ko) 2007-11-28 2016-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN102300872A (zh) 2009-02-02 2011-12-28 奥凯罗斯股份公司 猿腺病毒核酸和氨基酸序列，包含其的载体及其用途
CA2761457A1 (fr) 2009-05-12 2010-11-18 Transgene Sa Lignees cellulaires aviaires immortalisees et applications associees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136740A1 (en) * 2000-08-17 2002-09-26 Matti Sallberg Vaccines containing ribavirin and methods of use thereof
US20070269460A1 (en) * 2003-06-05 2007-11-22 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
WO2009056535A2 (fr) * 2007-10-29 2009-05-07 Genimmune N.V. Procédés et kits permettant d'induire une réponse de ltc en utilisant un schéma de primovaccination/rappel
WO2010117936A1 (fr) * 2009-04-06 2010-10-14 Schering Corporation Associations d'un inhibiteur du virus de l'hépatite c (vhc), tels des dérivés pyrroliques bicycliques, et d'un agent thérapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCOIS HABERSETZER ET AL: "A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 141, no. 3, 3 June 2011 (2011-06-03), pages 890 - 899.e4, XP028273467, ISSN: 0016-5085, [retrieved on 20110613], DOI: 10.1053/J.GASTRO.2011.06.009 *

Also Published As

Publication number Publication date
WO2013045668A2 (fr) 2013-04-04
TW201321016A (zh) 2013-06-01

Similar Documents

Publication Publication Date Title
PH12014500557A1 (en) Methods for treating hcv
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
MD20140058A2 (en) Compositions and methods for treating hepatitis C virus
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
BR112013028679A2 (pt) inibidores do vírus da hepatite c
ZA201403852B (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
IN2012MN02896A (fr)
WO2012006500A3 (fr) Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
SMT201700117T1 (it) Derivati di esadecaidrociclopropa(e)pirrolo(i ,2-a)(1,4)diazaciclopentadecinil carbammato sostituiti con 9-metile come inibitori della proteasi non strutturale 3 (ns3) per il trattamento delle infezioni da virus dell'epatite c
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112014010295A2 (pt) métodos e composições para o tratamento de vírus de hepatite c
WO2013036622A3 (fr) Peptides antiviraux efficaces contre le virus de l'hépatite c
WO2012162580A3 (fr) Composés antiviraux
WO2012162578A3 (fr) Composés antiviraux
IL225861A (en) Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs
PH12014500283A1 (en) Hcv immunotherapy
IN2015DN03925A (fr)
GB201008123D0 (en) Novel compounds
WO2013045668A3 (fr) Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c
NZ602552A (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2010081095A3 (fr) Procédés et compositions destinés à inhiber la réplication du virus de l'hépatite c
WO2012097123A3 (fr) Nouvelles utilisations d'inhibiteurs de la cyclophiline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12762658

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12762658

Country of ref document: EP

Kind code of ref document: A2